We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Idorsia AG (IDIA) CHF0.05

Sell:20.08 CHF Buy:20.10 CHF Change: 1.21 CHF (6.41%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
Sell:20.08 CHF
Buy:20.10 CHF
Change: 1.21 CHF (6.41%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
Sell:20.08 CHF
Buy:20.10 CHF
Change: 1.21 CHF (6.41%)
Market closed |  Prices as at close on 14 January 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Contact details

Address:
Hegenheimermattweg 91
ALLSCHWIL
4123
Switzerland
Telephone:
+ ()
Website:
https://www.idorsia.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IDIA
ISIN:
CH0363463438
Market cap:
3.34 billion CHF
Shares in issue:
176.95 million
Sector:
Biotechnology
Exchange:
SIX Swiss Exchange
Country:
Switzerland
Currency:
Swiss Franc
Indices:
n/a

Key personnel

  • Jean-Paul Clozel
    Chief Executive Officer, Delegate of the Board, Member of the Executive Board
  • Andre Muller
    Chief Financial Officer, Executive Vice President, Member of the Executive Board
  • Martine Clozel
    Executive Vice President, Chief Scientific Officer, Member of the Executive Board
  • Simon Jose
    Executive Vice President, Chief Commercial Officer, Member of the Executive Board
  • Guy Braunstein
    Executive Vice President, Head of Global Clinical Development, Member of the Executive Board

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.